A one-stop solution for early screening of Mild Cognitive Impairment (MCI) risk and personalized rehabilitation training
Virtual Brain VR Eye-tracking AI Analysis
Dementia Assessment and Personalized Rehabilitation Training
93.1% of participants were satisfied with the Virtual Brain VR dementia assessment
96.6% of participants found the evaluation helpful in understanding their brain health status
100% of participants were willing to recommend Virtual Brain VR dementia assessment to others
Virtual Brain VR Dementia Assessment
Accurately differentiates between normal cognition, mild cognitive impairment (MCI), and cognitive impairment risk
- Completed in 5 minutes
- Non-invasive and safe
- Integrating AI data to deliver real-time objective risk reports for cognitive impairment
- FDA class II & NMPA class II certifications
- Over 100,000 screenings completed
- Clinical data published in《Nature Partner Journal - Digital Medicine》 2024
- Validated through extensive clinical research and data verification of training effectiveness
Recognized by international authoritative organizations
NMPA Medical Device II Listed
US FDA Class II Listed
Using VR eye-tracking technology, AI analysis of gaze points, eye movement trajectories, eye heat map, gaze ratio amd other data to assess cognitive abilities in six features: Attention, Abstraction, Calculation, Execution, Memory, and Recall.
94% accuracy
This assessment achieves 94% accuracy and has been certified as FDA Class II and NMPA Class II. It enables detection of cognitive impairment risk at an early stage – the only phase where intervention may slow or improve symptoms – facilitating early discovery and timely management to effectively delay cognitive decline.
Virtual Brain Personalized Rehabilitation Training
Understanding risks and timely rehabilitation training can delay early cognitive impairment.
Based on eye movement assessment results, AI generates personalized training content by integrating six features of cognitive abilities.
Personalized training plan pinpointing cognitive deficiencies
Training progress monitoring
Immersive and amusing training games
At-home training is available
One of the keys to delaying MCI is to alleviate symptoms and slow disease progression through duly cognitive training. If symptoms develop to moderate or later stages, it is difficult to be reversed. Therefore, understanding the risk early and personalized cognitive training may assist to achieve the best improvement and slow disease progression.
Procedure for Use
Screening
VR combined with AI technology, capturing eye tracking data, screening of cognitive risk regularly
Rehabilitation Training
Regular Training Effectiveness Analysis
After completing the rehabilitation training course, analyze therapeutic effects through training progress and adjust the personalized training plan
Cognitive Impairment is divided into three stages.
Which stage is the most effective for treatment?
1: Normal Aging
Thinking and response times slow down
(MCI-AD)
2. Mild Cognitive Impairment
Memory begins to decline
(AD)
3.Late-Stage Alzheimer's Disease
Significant impact on daily living
Mild Cognitive Impairment (MCI-AD)
A Critical Stage for Delay AD
Once the condition progresses to Alzheimer’s disease, it deteriorates rapidly! Early detection of Alzheimer’s disease risk through timely screening allows for the delay of disease onset before further decline in cognitive abilities.
Patients with Mild Cognitive Impairment (MCI) are at high risk of developing Cognitive Impairment.
Approximately 10% to 15% of patients
with Mild Cognitive Impairment (MCI) will progress to Cognitive Impairment each year.
~15%
The risk of MCI patients
progressing to Cognitive Impairment is up to 10 times higher than that of the general elderly population.
MCI patients are at
10 times higher risk.
Once the condition progresses to Cognitive Impairment, cognitive decline becomes difficult to slow down or reverse.
Suitable Candidates for Testing
Aged 40 or above
Family History of AD
High-risk Factors of AD
Sign of Cognitive Decline is Observed
APOE4 Gene Carriers
Depression/Living with High Stress
Smoking or Heavy Drinking
